INTRODUCTION

Prosthesis-patient mismatch (PPM) can be considered after insertion into the patient when the effective orifice area (EOA) is of the prosthesis valve and is less than that of a normal human valve, which results in an increased postoperative transvalvular gradient.\textsuperscript{1,2} Previous studies reported that PPM after aortic valve replacement is associated with worse hemodynamics, decreased regression of left ventricular (LV) hypertrophy, more cardiac events and higher mortality.\textsuperscript{3-6} However, PPM after mitral valve replacement (MVR) has not been widely investigated, and its incidence has been reported to vary.\textsuperscript{7-10} In addition, studies on the clinical impact of PPM following MVR on survival have shown conflicting results, although two recent trials showed that PPM in the mitral position independently affects long-term survival.\textsuperscript{7,8} The most important reason for the discrepancy among the previous studies might be that the methods used to define PPM were different. Three different techniques have been used to calculate EOA, including the continuity equation (CE),\textsuperscript{7} pressure half time (PHT) method,\textsuperscript{10,11} and reference EOA.

Purpose: The incidence of prosthesis-patient mismatch (PPM) after mitral valve replacement (MVR) has been reported to vary. The purpose of the current study was to investigate incidence of PPM according to the different methods of calculating effective orifice area (EOA), including the continuity equation (CE), pressure half time (PHT) method and use of reference EOA, and to compare these with various echocardiographic variables.

Materials and Methods: We retrospectively reviewed 166 individuals who received isolated MVR due to rheumatic mitral stenosis and had postoperative echocardiography performed between 12 and 60 months after MVR. EOA was determined by CE (EOA\textsubscript{CE}) and PHT using Doppler echocardiography. Reference EOA was determined from the literature or values offered by the manufacturer. Indexed EOA was used to define PPM as present if ≤1.2 cm\textsuperscript{2}/m\textsuperscript{2}.

Results: Prevalence of PPM was different depending on the methods used to calculate EOA, ranging from 7% in PHT method to 49% in referred EOA method to 62% in CE methods. The intraclass correlation coefficient was low between the methods. PPM was associated with raised trans-prosthetic pressure, only when calculated by CE (p=0.021). Indexed EOA\textsubscript{CE} was the only predictor of postoperative systolic pulmonary artery (PA) pressure, even after adjusting for age, preoperative systolic PA pressure and postoperative left atrial volume index (p<0.001).

Conclusion: Prevalence of mitral PPM varied according to the methods used to calculate EOA in patients with mitral stenosis after MVR. Among the various methods used to define PPM, EOA\textsubscript{CE} was the only predictor of postoperative hemodynamic parameters.

Key Words: Mitral valve, heart valve prosthesis
systolic pulmonary artery (PA) pressure was defined as: 4×(maximal velocity of TR jet)$^2$+right atrial pressure. Right atrial pressure was estimated by the inferior vena cava diameter and its response to inspiration.$^{10,11}$ Doppler color flow mapping was used to assess the competency of the prosthetic valves.

**EOA calculation and definition of PPM**

Mitral valve EOA, calculated by CE (EOA$_{CE}$), was determined using the stroke volume measured in the LV outflow tract divided by the integral of the mitral valve trans-prosthetic velocity during diastole. Mitral valve EOA, calculated by PHT (EOA$_{PHT}$), was calculated using the formula 220/PHT.$^{21}$ Three cardiac cycles for patients in sinus rhythm and five for patients in atrial fibrillation were recorded, and the results were averaged for every patient. EOA$_{R}$ was determined from the literature or values offered by the manufacturer. EOA$_{CE}$, EOA$_{PHT}$, and EOA$_{R}$ were indexed for the body surface area (EOA$_{CEB}$, EOA$_{PHTB}$, and EOA$_{RB}$ respectively). Indexed EOA was used to define PPM as not significant if >1.2 cm$^2$/m$^2$, moderate if >0.9 cm$^2$/m$^2$ and ≤1.2 cm$^2$/m$^2$, and severe if ≤0.9 cm$^2$/m$^2$.7

**Statistical analysis**

The distributions of all relevant variables are reported as percentages or as mean±SD. The groups were compared using chi-square statistics for categorical variables and Student’s t-test for continuous variables. Correlation between the variables was assessed with the Pearson correlation test. Intraclass correlation coefficient (ICC) for a consistency was used to measure and compare agreement between EOA$_{CE}$ and EOA$_{PHT}$ and between EOA$_{R}$ and EOA$_{RB}$. Good correlation was defined as an ICC >0.8. To determine independent predictors of postoperative systolic PA pressure, linear relationships were checked with univariate linear regression analysis. Variables that had statistical significance in univariate analysis and EOA values were entered in the multiple linear regression model. A p value <0.05 was considered statistically significant.

**RESULTS**

Among the eligible 185 patients who underwent MVR due to mitral stenosis, 167 patients received postoperative echocardiography between 12 and 60 months after MVR. After excluding one patient who showed paravalvular leakage on postoperative echocardiography, the remaining 166 patients (age 56±11 years) with a median follow-up time of 16 months comprised the study population. Preoperative and postoperative variables of the studied populations are shown in Table 1. Of the 166 patients included in this study, there were 45 men and 121 women with a mean age of 56±11 years. Prevalence of hypertension and diabetes were 10% and 9%, respectively. Maze procedure and TV repair were performed in 42 (25%) and 66 (40%) patients, respectively, and atrial fibrillation during postoperative echocardiography was shown in 71 patients (43%).

http://dx.doi.org/10.3349/ymj.2016.57.2.328
Table 1. Characteristics of the Studied Population

| Variable                        | Value (n=166) |
|---------------------------------|---------------|
| Age at operation (yrs)          | 56±11         |
| Gender                          |               |
| Female                          | 121 (73%)     |
| Male                            | 45 (27%)      |
| Body surface area (m²)          | 1.58±0.25     |
| Hypertension                    | 17 (10%)      |
| Diabetes mellitus               | 15 (9%)       |
| Preoperative atrial fibrillation | 102 (61%)     |
| Maze procedure                  | 42 (25%)      |
| Tricuspid valve repair          | 66 (40%)      |
| Atrial fibrillation at follow-up| 71 (43%)      |
| Type of prosthesis              |               |
| Mechanical prosthesis           | 129 (78%)     |
| Bioprosthesis                   | 37 (22%)      |
| Prosthesis implanted            |               |
| St. Jude Mechanical             | 64 (39%)      |
| ATS                             | 29 (17%)      |
| On-X                            | 25 (15%)      |
| Carpentier Edwards Perimount    | 16 (10%)      |
| St. Jude Medical Epic           | 12 (7%)       |
| St. Jude Medical Biocor         | 7 (4%)        |
| Edwards MIRA                    | 7 (4%)        |
| SORIN                           | 4 (2%)        |
| Hancock II                      | 2 (1%)        |
| Prosthesis size (mm)            |               |
| 25                              | 22 (13%)      |
| 27                              | 76 (46%)      |
| 29                              | 62 (37%)      |
| 31                              | 6 (4%)        |
| MV EOAa (cm²)                   | 2.0±0.5       |
| MV EOAb (cm²/m²)                | 1.3±0.3       |
| Preoperative hemodynamics       |               |
| Systolic blood pressure, mm Hg  | 117±15        |
| Diastolic blood pressure, mm Hg | 74±10         |
| Heart rate, bpm                 | 73±16         |
| Preoperative echocardiography   |               |
| LVEF (%)                        | 62±9          |
| LVMi (g/m²)                     | 90±21         |
| LAVI (mL/m²)                    | 92±47         |
| TR grade≥moderate               | 50 (33%)      |
| Systolic PA pressure (mm Hg)    | 41±14         |
| Mitral valve area by 2-dimensional planimetry (cm²) | 0.9±0.2 |
| Postoperative hemodynamics      |               |
| Systolic blood pressure, mm Hg  | 119±15        |
| Diastolic blood pressure, mm Hg | 74±11         |
| Heart rate, bpm                 | 71±11         |
| Postoperative echocardiography  |               |
| LVEF (%)                        | 64±6          |
| LVMi (g/m²)                     | 113±28        |
| LAVI (mL/m²)                    | 60±33         |

Table 1. Characteristics of the Studied Population (Continued)

| Variable                        | Value (n=166) |
|---------------------------------|---------------|
| TR grade≥moderate               | 17 (10%)      |
| Systolic PA pressure (mm Hg)    | 27±7          |
| Mean diastolic trans-prosthetic gradient (mm Hg) | 3.5±1.2 |
| MV EOAb (cm²)                   | 1.8±0.5       |
| MV EOAb (cm²/m²)                | 2.6±0.5       |
| MV EOAb (cm²/m²)                | 1.2±0.3       |
| MV EOAb (cm²/m²)                | 1.7±0.4       |

MV, mitral valve; EOAa, referred effective orifice area; EOAb, referred effective orifice area index; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; LAVI, left atrial volume index; TR, tricuspid regurgitation; PA, pulmonary artery; 2D, 2-dimensional; EOAb, measured effective orifice area index by continuity equation; EOAb, measured effective orifice area index by pressure half time; EOAb, measured effective orifice area index by pressure half time. St. Jude Mechanical (St. Jude Medical, Minneapolis, MN, USA); ATS (ATS Medical, Minneapolis, MN, USA); On-X (MICR, Austin, TX, USA); Carpentier Edwards Perimount (Edwards Lifesciences, Irvine, CA, USA); St. Jude Medical Epic (St. Jude Medical, Minneapolis, MN, USA); St. Jude Medical Biocor (St. Jude Medical, Minneapolis, MN, USA); Edwards MIRA (Edwards Lifesciences, Irvine, CA, USA); SORIN (SORIN-Biomedica, Saluggia, Italy); Hancock II (Medtronic, Inc., Minneapolis, MN, USA).

Fig. 1 shows the prevalence of mitral valve PPM according to the methods used to calculate EOA. Prevalence ranged from 7% in PHT method to 49% in referred EOA method to 62% in CE method. There were 63 patients without PPM (38%), 80 patients with moderate PPM (48%) and 23 patients with severe PPM (14%), when EOAb was used to define PPM. In contrast, the prevalence of moderate and severe PPM was relatively very low [8 patients (5%) and 3 patients (2%), respectively] according to EOAb. There were 85 patients without PPM (51%), 73 patients with moderate PPM (44%) and 8 patients with severe PPM (5%) according to EOAb.

Comparison of characteristics according to the method of PPM calculation is shown in Table 2. When PPM was defined by EOAb, the prevalence of males was higher, body surface area was greater and trans-prosthetic pressure and postoperative systolic PA pressure were higher in the PPM group. When PPM was defined by EOAb, age at operation and prevalence of atrial fibrillation at follow-up were higher and left atrial volume index (LAVI) was larger in the PPM group. When we used EOAb, prevalence of atrial fibrillation at follow-up and postoperative LV ejection fraction was higher in the PPM group. There were no significant differences in prevalence of moderate or greater TR at preoperative echocardiography between the groups in all three methods. However, there was a tendency of high occurrence of moderate or greater TR at postoperative echocardiography in PPM group, only when PPM was defined according to CE (p=0.069).

Correlations between EOAb and EOAb, between EOAb and EOAb and between EOAb and EOAb are demonstrated in Fig. 2. All the agreements between EOAb and EOAb, between EOAb and EOAb and between EOAb and EOAb were poor [0.430, 95% confidence interval (CI) 0.226–0.580; 0.320,
95% CI 0.077–0.500; and 0.362, 95% CI 0.133–0.530, respectively). When the patients were divided into two groups according to the presence of PPM using various methods, the results of correlation were similar. CE methods poorly correlated with referred method (ICC=0.249) and PHT method (ICC=0.228) in defining PPM. Correlation between referred and PHT method was also poor (ICC=0.306).

Fig. 3 shows the correlation between indexed EOAs and postoperative systolic PA pressure. Among the indexed EOAs, EOAI_{CE} showed significant correlation with postoperative systolic PA pressure (r=-0.384, p<0.001). In contrast, there were no significant correlations between EOAI_{PHT} and postoperative systolic PA pressure (r=-0.089, p=0.254) or between EOAI_{R} and postoperative systolic PA pressure (r=-0.110, p=0.158). Linear regression analysis was performed to identify the predictors of postoperative systolic PA pressure as a dependent variable (Table 2). On multivariate regression, age, mitral valve EOAI_{CE}, and postoperative LAVI were found to be independent predictor of postoperative systolic PA pressure (p=0.002, p<0.001, and p=0.001, respectively) (Table 3). On the contrary, EOAI_{PHT} and EOAI_{R} were not predictors for postoperative systolic PA pressure.

Fig. 4 compares of postoperative systolic PA pressure among the patients without PPM (n=63), with moderate PPM (n=80) and with severe PPM (n=23) according to EOAI_{CE}. Systolic PA pressure was statistically different between the patients without PPM and with moderate PPM (25±6 mm Hg vs. 28±6 mm Hg, p=0.007), as well as between patients with moderate and severe PPM (28±6 mm Hg vs. 33±11 mm Hg, p=0.037).

**DISCUSSION**

The principal findings of the present study are that 1) the incidence of PPM after MVR in patients with mitral stenosis was variable according to the different methods of determining EOA, and 2) among the EOAs assessed by 3 different methods, including the CE method, PHT method and use of reference values, only the EOAI_{CE} was found to be independently associated with the postoperative systolic PA pressure.

**Conflicting data on PPM after MVR**

Since first described in 1978, PPM after MVR has been suggested to correlate with poor clinical outcomes including persistent pulmonary hypertension and late functional TR. However, some authors have insisted that PPM did not affect survival after MVR, although several recent trials suggested that mitral PPM independently affects long-term survival. In addition, the overall incidence of PPM (<1.3 to <1.2 cm²/m²) after MVR has been shown to vary, ranging from 3.7% to 85.9%. The incidence of moderate PPM has also been reported to vary, ranging from 37.4% to 69.5%, and the incidence of severe PPM ranged from 8.7% to 16.4%.

**Explanations for discrepancy**

There may be several explanations concerning the conflicting data on the clinical effect of PPM after MVR. First, different valve types and patients groups were employed in the studies. Especially, patients suffering PPM have sometimes additional risk factors, including hypertension and diabetes, which could also affect long-term survival. Second, when evaluating the impact of PPM after MVR, it is also important to consider pathophysiological status of patients. In the current study, minimize those problems, we included only patients with rheumatic mitral stenosis and analyzed postoperative echocardiography 12 to 60 months after MVR, thus avoiding dynamic changes of hemodynamic status at early postoperative period and the late development of prosthetic valve malfunction which might be...
associated with pannus formation. Consequently, we found that PPM determined by CE showed significant correlation with various postoperative hemodynamic parameters.

Methods to determine effective orifice area
The most important reason for discrepancy among the previous studies might be that the methods used to define PPM were different. In previous studies, three different methods have

Table 2. Characteristics of the Study Population According to the Method of Prosthesis-Patient Mismatch Determination

| Variable                          | No PPM (n=63) | PPM (n=103) | p value | No PPM (n=155) | PPM (n=11) | p value | No PPM (n=85) | PPM (n=81) | p value |
|-----------------------------------|---------------|-------------|---------|----------------|-------------|---------|----------------|-------------|---------|
| Age at operation (yrs)            | 56±11         | 56±11       | 0.810   | 56±11          | 64±9        | 0.016   | 55±11          | 57±11       | 0.211   |
| Gender                            |               |             |         |                |             |         |                |             |         |
| Female                            | 51 (81%)      | 70 (68%)    |         | 114 (74%)      | 7 (64%)     | 0.001   | 66 (78%)       | 55 (68%)    | 0.718   |
| Male                              | 12 (19%)      | 33 (32%)    |         | 41 (26%)       | 43 (38%)    |         | 19 (22%)       | 26 (32%)    |         |
| Body surface area (m²)            | 1.53±0.15     | 1.60±0.14   | 0.001   | 1.57±0.15      | 1.63±0.15   | 0.209   | 1.55±0.15      | 1.61±0.14   | 0.211   |
| Hypertension                      | 6 (10%)       | 11 (11%)    | 0.517   | 13 (8%)        | 43 (38%)    | 0.016   | 8 (9%)         | 9 (11%)     | 0.718   |
| Diabetes mellitus                 | 5 (8%)        | 10 (10%)    | 0.465   | 14 (9%)        | 1 (6%)      | 0.659   | 7 (8%)         | 8 (10%)     | 0.712   |
| Preoperative atrial fibrillation   | 40 (63%)      | 62 (60%)    | 0.399   | 91 (69%)       | 11 (100%)   | 0.004   | 45 (54%)       | 57 (70%)    | 0.021   |
| Maze procedure                    | 19 (30%)      | 23 (22%)    | 0.895   | 41 (26%)       | 1 (6%)      | 0.090   | 23 (27%)       | 19 (23%)    | 0.130   |
| Tricuspid valve repair            | 27 (43%)      | 39 (38%)    | 0.524   | 61 (39%)       | 5 (45%)     | 0.690   | 29 (34%)       | 37 (46%)    | 0.128   |
| Atrial fibrillation at follow-up  | 26 (41%)      | 45 (44%)    | 0.443   | 62 (40%)       | 9 (82%)     | 0.007   | 29 (34%)       | 42 (52%)    | 0.016   |
| Type of prosthesis                | 0.242         |             |         | 0.001          |             |         | 0.008          |             |         |
| Mechanical prosthesis             | 52 (83%)      | 77 (75%)    |         | 125 (81%)      | 4 (36%)     |         | 73 (86%)       | 56 (69%)    |         |
| Bioprosthesis                     | 11 (17%)      | 26 (25%)    |         | 30 (19%)       | 7 (64%)     |         | 12 (14%)       | 25 (31%)    |         |
| Prosthesis size (mm)              | 0.484         | 0.307       |         | 0.356          |             |         |                |             |         |
| LVEF (%)                          | 62±9          | 62±9        | 0.762   | 64±6           | 62±5        | 0.389   | 62±8           | 62±9        | 0.585   |
| LVMI (g/m²)                       | 87±23         | 92±20       | 0.145   | 89±20          | 113±21      | 0.122   | 91±22          | 89±20       | 0.585   |
| LAVI (mL/m²)                      | 110±31        | 114±26      | 0.444   | 89±43          | 135±71      | 0.057   | 92±43          | 93±50       | 0.868   |
| TR grade≥moderate                 | 22 (35%)      | 28 (27%)    | 0.292   | 48 (31%)       | 2 (18%)     | 0.372   | 25 (29%)       | 25 (31%)    | 0.838   |
| Systolic PA pressure (mm Hg)      | 43±14         | 40±14       | 0.169   | 41±14          | 40±9        | 0.832   | 39±11          | 43±16       | 0.051   |
| Mitral valve area by 2D planimetry (cm²) | 0.9±0.2 | 0.9±0.2 | 0.236 | 0.9±0.2 | 0.8±0.2 | 0.158 | 0.9±0.2 | 0.9±0.2 | 0.264 |
| Postoperative echocardiography    |               |             |         |                |             |         |                |             |         |
| LVEF (%)                          | 64±6          | 63±6        | 0.245   | 64±6           | 62±5        | 0.389   | 62±6           | 65±5        | 0.013   |
| LVMI (g/m²)                       | 103±56        | 86±39       | 0.131   | 111±27         | 131±39      | 0.122   | 114±29         | 112±27      | 0.626   |
| LAVI (mL/m²)                      | 66±42         | 57±24       | 0.089   | 59±31          | 85±43       | 0.008   | 58±30          | 63±35       | 0.380   |
| TR grade≥moderate                 | 3 (5%)        | 14 (14%)    | 0.069   | 15 (10%)       | 2 (18%)     | 0.369   | 9 (11%)        | 8 (10%)     | 0.880   |
| Mean diastolic trans-prosthetic gradient (mm Hg) | 3.2±1.1 | 3.7±1.2 | 0.021 | 3.4±1.2 | 3.4±1.5 | 0.844 | 3.4±1.3 | 3.4±1.0 | 0.915 |
| Systolic PA pressure (mm Hg)      | 25±6          | 29±8        | 0.001   | 27±7           | 29±9        | 0.381   | 27±7           | 28±8        | 0.440   |
| MV EOAI(cm²)                      | 2.2±0.4       | 1.6±0.2     | <0.001  | 1.8±0.5        | 1.6±0.3     | 0.120   | 1.8±0.5        | 1.8±0.5     | 0.520   |
| MV EOAI(cm²/m²)                   | 2.6±0.5       | 2.6±0.5     | 0.014   | 2.7±0.4        | 1.7±0.3     | <0.001  | 2.7±0.5        | 2.6±0.5     | 0.114   |
| MV EOAI(cm²/m²)                   | 1.5±0.2       | 1.0±0.1     | <0.001  | 1.2±0.3        | 1.0±0.2     | 0.029   | 1.2±0.3        | 1.1±0.3     | 0.083   |
| MV EOAI(cm²/m²)                   | 1.8±0.4       | 1.6±0.3     | <0.001  | 1.8±0.3        | 1.1±0.2     | <0.001  | 1.8±0.4        | 1.6±0.3     | 0.007   |

MV, mitral valve; EOAI, referred effective orifice area; EOAI(cm²/m²), measured effective orifice area index by continuity equation; EOAI(cm²/m²), measured effective orifice area index by pressure half time; EOAI(cm²/m²), measured effective orifice area index by pressure half time half.
been used to calculate EOA, including the CE method, PHT method, and reference EOA. We compared the three methods and found that agreement among EOA_{CE}, EOA_{PHT}, and EOA was poor, and the prevalence of PPM varied according to the calculation method, ranging from 7% in the PHT method to 49% in the reference EOA method to 62% in the CE method. This finding explains the discrepant prevalence of PPM and conflicting data about the prognosis of PPM in the various studies. Long-term survival data of patients with PPM defined by EOA_{CE} has not yet been reported, and further studies with EOA_{CE} might be necessary to clarify the clinical impact of PPM.

Interestingly, it has been reported in the previous reports that prevalence of PPM was relatively high when CE was used to define PPM, ranging from 42% to 71%. We also found similar results of high prevalence of PPM, especially in moderate PPM. Possible explanation is that in bileaflet valves, the smaller central orifice has a higher velocity than the larger outside orifice, which may lead to underestimation of EOA_{CE}. Patients who underwent MVR with bileaflet mechanical heart valve were 78% in the current study, and therefore, there is a chance that EOA_{CE} might be underestimated in part. Therefore, further research and overall agreement are required to establish the allowable range of EOA_{CE} for the definition of PPM, although CE methods might be the most appropriate method to determine EOA. In addition, clinical implication of moderate PPM in mitral position is not clear, since moderate PPM did not show statistically significant result of poor survival, contrast to severe PPM, which showed poor long-term survival. Nevertheless, we demonstrated that even patients with moderate PPM showed raised systolic PA pressure compared to those without PPM, suggesting clinical significance of moderate PPM. Therefore, the clinical impact of moderate PPM and EOA range for the diagnosis of PPM might need further investigation.

Among the three methods, mentioned above EOA_{PHT} is not recommended for calculating EOA of the mitral prosthesis because of the influence of chronotropic conditions and atrioventricular compliance. Nevertheless, some studies still use PHT method to define EOA. In the current study, as anticipated, EOA calculation via the PHT method was found to be not associated with postoperative hemodynamic parameters and largely overestimated the EOA compared to other methods. Therefore, we should try not to use PHT to calculate EOA in mitral prosthesis.

**Pulmonary artery pressure after MVR**

A rise in PA pressure can result from elevation of pulmonary blood flow, pulmonary venous pressure and/or vascular resis-

---

**Fig. 2.** Correlation between EOA_{CE} and EOA_{PHT} (A), between EOA_{CE} and EOA_{R} (B) and between EOA_{PHT} and EOA_{R} (C). EOA_{CE}, measured effective orifice area index by continuity equation; EOA_{PHT}, measured effective orifice area index by pressure half time; EOA_{R}, referred effective orifice area index.

**Fig. 3.** Correlations between effective orifice area index and postoperative systolic PA pressure. (A) Effective orifice area index by continuity equation, (B) effective orifice area index by pressure half time, and (C) referred effective orifice area index. PA, pulmonary artery; EOA_{CE}, measured effective orifice area index by continuity equation; EOA_{PHT}, measured effective orifice area index by pressure half time; EOA_{R}, referred effective orifice area index.
tance, and pulmonary hypertension is an important risk factor for morbidity and mortality in patients with various cardiovascular diseases. Pulmonary hypertension is frequently observed in patients with mitral stenosis. Since increased PA pressure is associated with poor functional capacity and a dismal prognosis in patients with severe mitral valve disease, normalization of PA pressure constitutes a crucial goal of MVR.

The development of late TR after MVR is an important complication of the surgery, since it is associated with a severe impairment of exercise capacity and a poor symptomatic outcomes. However, the pathogenesis of this condition remains poorly understood, and treatment for the patients with late TR is clinically difficult to decide. Recently, it has been reported that mitral PPM is associated with the persistence of TR and pulmonary hypertension following MVR. Our study also demonstrated similar results, showing a tendency of high prevalence in moderate or greater TR in PPM group, defined by CE. In addition, PPM calculated by EOAI showed higher trans-prosthetic pressure, and EOAI was the only parameter which showed independent correlation with postoperative systolic PA pressure. Systolic PA pressure has been known to be influenced by many factors including age, diastolic dysfunction and cardiopulmonary disease, as well as trans-prosthetic pressure. Since we enrolled homogenous, relatively young patient population of pure mitral stenosis, we can speculate that mitral PA pressure might be influenced mainly by trans-prosthetic gradient in the studied population. Therefore, the use of EOAI rather than EOAI and EOAI may be appropriate for identifying PPM in the mitral position, since hemodynamic variables, including trans-prosthetic pressure and systolic PA pressure, showed significant correlation with EOA, only when it is calculated by using CE.

Unfortunately, however, most previous studies on PPM after MVR used EOAI to define PPM. EOAI was used to define PPM in only two studies, and both demonstrated clinical significance of PPM after MVR, including association with persistent pulmonary hypertension and late TR. Therefore, further larger studies to define PPM using EOAI are needed to clarify clinical significance and implications of PPM after MVR.

### Limitations

The results of the study were based on retrospective analysis; however, we carefully reviewed patient medical records and echocardiography. As our findings are based upon an observational cohort of patients with rheumatic mitral stenosis, they may not necessarily be generalizable to all patients with mitral regurgitation. We compared indexed EOA to systolic PA pressure, not clinical outcome, since the studied group was at relatively low risk for cardiovascular events, as indicated by the low prevalence of combined co-morbidities such as hypertension and diabetes. In addition, functional data, such as maximum exercise capacity and maximum oxygen consumption, which would be more helpful for identifying the clinical implication of mitral PPM, were not included. Prevalence of pulmonary hypertension (systolic PA pressure >40 mm Hg) was relatively low, and therefore, further investigation into the clinical significance of the results of the current study is needed. Patients with atrial fibrillation were included in the study population, although five cardiac cycles were recorded and these results were averaged. We used linear regression analysis to determine independent predictors of systolic PA pressure, although we cannot conclude that there is no association just because the linear regression analysis failed to demonstrate a significant relationship. Therefore, further studies to define PPM using EOAI are needed to clarify clinical significance and implications of PPM after MVR.

### Table 3. Multivariate Regression Analysis for the Predictors of Systolic PA Pressure after Mitral Valve Replacement

| Variable | β coefficient | 95% CI | p value |
|----------|---------------|--------|---------|
| **Model 1** | | | |
| Age at operation | 0.23 | 0.06 to 0.26 | 0.002 |
| Preoperative systolic PA pressure | 0.09 | -0.02 to 0.12 | 0.179 |
| Postoperative LAVI | 0.25 | 0.02 to 0.09 | 0.001 |
| Mitral valve EOAI | -0.37 | -12.2 to -5.8 | <0.001 |
| **Model 2** | | | |
| Age at operation | 0.28 | 0.08 to 0.30 | 0.001 |
| Preoperative systolic PA pressure | 0.07 | -0.04 to 0.11 | 0.324 |
| Postoperative LAVI | 0.23 | 0.02 to 0.09 | 0.006 |
| Mitral valve EOAI | -0.04 | -3.68 to 1.95 | 0.543 |
| **Model 3** | | | |
| Age at operation | 0.27 | 0.07 to 0.29 | 0.001 |
| Preoperative systolic PA pressure | 0.06 | -0.04 to 0.11 | 0.402 |
| Postoperative LAVI | 0.23 | 0.02 to 0.09 | 0.004 |
| Mitral valve EOAI | -0.05 | -4.28 to 2.00 | 0.474 |

CI, confidence interval; PA, pulmonary artery; EOAI, measured effective orifice area index by continuity equation; LAVI, left atrial volume index; EOAI, measured effective orifice area index by pressure half time; EOAI, referred effective orifice area index.

![Fig. 4. Comparison of postoperative systolic PA pressure among patients without PPM (n=63) to those with moderate PPM (n=80) and with severe PPM (n=23), defined using the continuity equation. Vertical bars represent range, boxes represent inter-quartile range, and horizontal lines represent the median. PPM, prosthesis-patient mismatch; PA, pulmonary artery.](http://dx.doi.org/10.3349/ymj.2016.57.2.328)
gression is not significant. Nevertheless, the association with EOA\textsubscript{PET} and EOA\textsubscript{A} is unlikely, since there were no significant differences in systolic PA pressure between the groups, and the multivariate regression analysis showed that EOA\textsubscript{PET} and EOA\textsubscript{A} were not predictors of systolic PA pressure.

REFERENCES

1. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. Circulation 1978;58:20-4.
2. Pibarot P, Dumesnil JG, Cartier PC, Métras J, Lemieux MD. Patient-prosthesis mismatch can be predicted at the time of operation. Ann Thorac Surg 2001;71(S Suppl):S265-8.
3. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. Heart 2006;92:1022-9.
4. Angeloni E, Melina G, Pibarot P, Benedetto U, Refice S, Bavarella GM, et al. Impact of prosthesis-patient mismatch on the regression of secondary mitral regurgitation after isolated aortic valve replacement with a bioprosthetic valve in patients with severe aortic stenosis. Circ Cardiovasc Imaging 2012;5:36-42.
5. Melina G, Angeloni E, Benedetto U, Refice S, Miceli A, Miele C, et al. Relationship between prosthesis-patient mismatch and pro-brain natriuretic peptides after aortic valve replacement. J Heart Valve Dis 2010;19:171-6.
6. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ, et al. The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 816 patients with 133 141 patient-years. Eur Heart J 2012;33:1518-29.
7. Magne J, Mathieu P, Dumesnil JG, Tanné D, Dagenais F, Doyle D, et al. Impact of prosthesis-patient mismatch on survival after mitral valve replacement. Circulation 2007;115:1417-25.
8. Lam BK, Chan V, Hendry P, Ruel M, Masters R, Bedard P, et al. The impact of patient-prosthesis mismatch on late outcomes after mitral valve replacement. J Thorac Cardiovasc Surg 2007;133:1464-73.
9. Li M, Dumesnil JG, Mathieu P, Pibarot P. Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement. J Am Coll Cardiol 2005;45:1034-40.
10. Sakamoto H, Watanabe Y. Does patient-prosthesis mismatch affect long-term results after mitral valve replacement? Ann Thorac Cardiovasc Surg 2010;16:163-7.
11. Matsuura K, Mogi K, Aoki C, Takahara Y. Prosthesis-patient mismatch after mitral valve replacement stratified by referred and measured effective valve area. Ann Thorac Cardiovasc Surg 2011;17:153-9.
12. Aziz A, Lawton JS, Maniar HS, Pasque MK, Damiano RJ Jr, Moon MR. Factors affecting survival after mitral valve replacement in patients with prosthesis-patient mismatch. Ann Thorac Surg 2010;90:1202-10.
13. Bouchard D, Vanden Eynden F, Demers P, Perrault LP, Carrier M, Cartier R, et al. Patient-prosthesis mismatch in the mitral position affects midterm survival and functional status. Can J Cardiol 2010;26:532-6.
14. Jamieson WR, Germaan E, Ye J, Chan F, Cheung A, MacNab JS, et al. Effect of prosthesis-patient mismatch on long-term survival with mitral valve replacement: assessment to 15 years. Ann Thorac Surg 2009;87:1135-41.
15. Shi WY, Yap CH, Hayward PA, Dinh DT, Reid CM, Shardey GC, et al. Impact of prosthesis--patient mismatch after mitral valve replacement: a multicentre analysis of early outcomes and mid-term survival. Heart 2011;97:1074-81.
16. Dumesnil JG, Pibarot P. Prosthesis-patient mismatch: an update. Curr Cardiol Rep 2011;13:250-7.
17. Zoghbi WA, Chambers JB, Dumesnil JG, Foster E, Gottdiener JS, Grayburn PA, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009;22:975-1014.
18. Devereux RB, Alonso DR, Lutas EM, Gottlieb DJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
19. Sanfilippo AJ, Abascal VM, Shuehan M, Oertel LB, Harrigan P, Hughes RA, et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation 1990;82:792-7.
20. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
21. Hatle L, Angelsen B, Tromsdal A. Noninvasive assessment of atriopulmonary pressure half-time by Doppler ultrasound. Circulation 1979;60:1096-104.
22. Zhang J, Wu YC, Shen WF, Kong Y. Impact of prosthesis-patient mismatch on survival after mitral valve replacement: a systematic review. Chin Med J (Engl) 2013;126:3762-6.
23. Angeloni E, Melina G, Benedetto U, Rosciano A, Refice S, Quarto C, et al. Impact of prosthesis-patient mismatch on tricuspid valve regurgitation and pulmonary hypertension following mitral valve replacement. Int J Cardiol 2013;168:4150-4.
24. Schwammenthal E, Vered Z, Agranat O, Kaplinsky E, Rabinowitz B, Feinberg MS. Impact of atrioventricular compliance on pulmonary artery pressure in mitral stenosis: an exercise echocardiographic study. Circulation 2000;102:2378-84.
25. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, De Kre M, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
26. Malouf JF, Enriquez-Sarano M, Pellikka PA, Oh JK, Bailey KR, Chandrasekaran K, et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. J Am Coll Cardiol 2002;40:789-95.
27. Enriquez-Sarano M, Rossi A, Seward JB, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997;29:153-9.
28. Vincens JJ, Temizer D, Edmunds LH Jr, Herrmann HC. Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension. Circulation 1995;92(9 Suppl):I137-42.
29. Crawford MH, Soucek J, Oprim CA, Miller DC, Rahimtoola S, Gibbons J, et al. Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 1990;81:1173-81.
30. Lee S, Lee SH, Chang BC, Shim JK. Efficacy of goal-directed thera-

http://dx.doi.org/10.3349/ymj.2016.57.2.328
31. Groves PH, Hall RJ. Late tricuspid regurgitation following mitral valve surgery. J Heart Valve Dis 1992;1:80-6.

32. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009;119:2663-70.